Research & Development
Scientific Overview
Scientific Presentations
Scientific Advisory Board
Clinical Studies
Clinical Trial Participation
Clinical Trial Sites
Pre-Clinical
Research
Product Pipeline
Scientific Reports
 |
||||||||||
 |
 |
|||||||||
 |
 |
 |
 |
 |
||||||
 |
 |
|||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
Adjunct Treatment in Bypass Patients | |||||||||
|
In addition to using FGF-1141 as the sole therapy to treat no-option heart patients, we are also developing clinical protocols to test the application of FGF-1141 in patients who are receiving a bypass procedure. The idea in this clinical trial will be to examine the effect of treating areas of the heart with FGF-1141 where ischemia is due to the blockage of smaller vessels that cannot be surgically treated during the bypass procedure. Previous clinical studies with FGF-1141 indicated that patients receiving both a bypass and injection of the growth factor experience longer lasting relief from angina than patients only receiving a bypass.
<<< Return to Treatment Applications
Use of
this site constitutes agreement to our Terms and Conditions Some content on this site requires the free Adobe
Reader. | ||||||||||
 |
||||||||||
 |
|
|
|
|
|
|
|
|
|
|
12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
11/13/2008
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
9/9/2008
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial